Following the FDA black box warning in 2004, substantial reductions in antidepressant (ATD) use were observed within 2 years in children and adolescents in several countries. However, whether these reductions were sustained is not known. The objective of this study was to assess more recent trends in ATD use in youth (0-19 years) for the calendar years 2005/6-2012 using data extracted from regional or national databases of Denmark, Germany, the Netherlands, the United Kingdom (UK), and the United States (US). In a repeated cross-sectional design, the annual prevalence of ATD use was calculated and stratified by age, sex, and according to subclass and specific drug. Across the years, the prevalence of ATD use increased from 1.3% to 1.6% in t...
Background: The use of antidepressants in children and adolescents remains controversial. We examine...
Drug utilization studies have applied different methods to various data types to describe medication...
In 2003, the Committee on Safety of Medicines (CSM) advised against treatment with selective seroton...
Following the FDA black box warning in 2004, substantial reductions in antidepressant (ATD) use were...
Objective To compare antidepressant prevalence data in youths across three western European countrie...
Objective To compare antidepressant prevalence data in youths across three western European countrie...
Over the last two decades, the use of ADHD medication in US youth has markedly increased. However, l...
Aims: To characterise prescribing patterns of antidepressants (ATDs) to children and adolescents age...
PURPOSE: Recent studies on the utilization of antidepressant drugs in minors are scarce, methodologi...
Purpose: Drug utilization studies have applied different methods to various data types to describe m...
Purpose: Drug utilization studies have applied different methods to various data types to describe m...
In 2003–2004 and 2007–2008, the regulatory banning of SSRI use in pediatrics and young adults due to...
In 2003-2004 and 2007-2008, the regulatory banning of SSRI use in pediatrics and young adults due to...
BACKGROUND: In 2003, the Irish Medicines Board (IMB) warned against the treatment of childhood depre...
Until recently, the use of antidepressant (ATD) drugs by young people for the treatment of psychiatr...
Background: The use of antidepressants in children and adolescents remains controversial. We examine...
Drug utilization studies have applied different methods to various data types to describe medication...
In 2003, the Committee on Safety of Medicines (CSM) advised against treatment with selective seroton...
Following the FDA black box warning in 2004, substantial reductions in antidepressant (ATD) use were...
Objective To compare antidepressant prevalence data in youths across three western European countrie...
Objective To compare antidepressant prevalence data in youths across three western European countrie...
Over the last two decades, the use of ADHD medication in US youth has markedly increased. However, l...
Aims: To characterise prescribing patterns of antidepressants (ATDs) to children and adolescents age...
PURPOSE: Recent studies on the utilization of antidepressant drugs in minors are scarce, methodologi...
Purpose: Drug utilization studies have applied different methods to various data types to describe m...
Purpose: Drug utilization studies have applied different methods to various data types to describe m...
In 2003–2004 and 2007–2008, the regulatory banning of SSRI use in pediatrics and young adults due to...
In 2003-2004 and 2007-2008, the regulatory banning of SSRI use in pediatrics and young adults due to...
BACKGROUND: In 2003, the Irish Medicines Board (IMB) warned against the treatment of childhood depre...
Until recently, the use of antidepressant (ATD) drugs by young people for the treatment of psychiatr...
Background: The use of antidepressants in children and adolescents remains controversial. We examine...
Drug utilization studies have applied different methods to various data types to describe medication...
In 2003, the Committee on Safety of Medicines (CSM) advised against treatment with selective seroton...